


SUPPLEMENTARY FIGURE



Supplementary Figure 1. (A–L) Analysis of drug susceptibility in risk model. (A) BI-2536, (B) Daporinad, (C) Sepantronium bromide, (D) UMI-77, (E) Telomerase Inhibitor IX, (F) Pyridostatin, (G) AZD6482, (H) Entinostat, (I) Mitoxantrone, (J) Ribociclib, (K) RVX-208, (L) Venetoclax.